News Search Results
Jun 15, 2026, 23:25 ET The 7th Qingdao Multinationals Summit Kicks Off: Joining Hands for the 15th Five-Year Plan to Build a New Ecosystem of Openness and Cooperation
the service sector this year. The Ministry of Commerce is set to steadily implement pilot opening initiatives in value-added telecommunications, biotechnology, and wholly foreign-owned hospitals, alongside improving the regulatory framework for the cross-border trade in services negative list. Earlier
More news about: Information Office of the People's Government of Shandong Province
Jun 15, 2026, 14:45 ET Kalohexis Presents Data Highlighting Dual MC3R/MC4R Activation as a Novel Mechanism Designed to Drive Safer, Healthier and More Durable Weight Loss at ENDO 2026
NORTHBROOK, Ill., June 15, 2026 /PRNewswire/ -- Kalohexis Inc., a clinical-stage biotechnology company harnessing the melanocortin system to shape the next era of metabolic disease care starting with obesity and cancer cachexia, announced
More news about: Kalohexis
Jun 15, 2026, 13:26 ET Laboratory Filtration Market Eyes US$ 6.8 Bn by 2030: Latest Report by Wissen Research
The laboratory filtration market is experiencing steady growth, driven by increasing pharmaceutical and biotechnology research, expanding biopharmaceutical production, and rising demand for high-purity sample preparation and quality control, says Mayur Jain,
More news about: Wissen Research LLC
Jun 15, 2026, 12:52 ET BetterAge Strengthens Executive Leadership Team to Accelerate Partnerships, Innovation, and Impact
Information Security Officer at On Lok and has spent more than 20 years leading technology, analytics, and cybersecurity initiatives across healthcare, biotechnology, higher education, and nonprofit organizations."Data and AI give us new opportunities to understand what drives healthy aging and measure
More news about: BetterAge
Jun 15, 2026, 11:46 ET Four Rubin Rudman Partners Named to 2026 Lawdragon 500 X - The Next Generation
Rubin Rudman serves national and international companies, including large public companies and closely held businesses; real estate developers; biotechnology, pharmaceutical and medical device makers; hospitality companies; regulated industries, public entities and municipalities; insurance companies
More news about: Rubin Rudman
Jun 15, 2026, 10:30 ET Stem Cell Therapy Market worth $3.65 billion by 2035 | MarketsandMarkets™
(UK).Browse Adjacent Markets: Biotechnology Market Research Reports & ConsultingRelated Reports:
More news about: MarketsandMarkets
Jun 15, 2026, 10:25 ET 2026 Merkin Prize in Biomedical Technology awarded to pioneers of the modern cochlear implant
from MIT, Harvard, Harvard's primary teaching hospitals, other academic institutions, and leading corporate partners in the pharmaceutical and biotechnology industries, all of whom share the goal of translating research findings into safe and effective therapeutic interventions for all common and rare
More news about: Broad Institute
Jun 15, 2026, 10:15 ET Companion Diagnostics Market worth $11.57 billion by 2031 | MarketsandMarkets™
Insights:The assays, kits & reagents segment captured 67.3% of the total market in 2025.Pharmaceutical & biotechnology companies dominated the companion diagnostics market in 2025.North America accounted for the largest share of 44.7% in 2025.Download
More news about: MarketsandMarkets
Jun 15, 2026, 08:55 ET Scientist.com to Host Expert Webinar on New Approach Methodologies for Drug Discovery and Development
workflowsScientist.com powers secure, private marketplaces for many of the world's largest pharmaceutical companies and hundreds of biotechnology firms, helping them digitize, harmonize and manage scientific purchasing across the full R&D lifecycle. The company is headquartered in Solana
More news about: Scientist.com
Jun 15, 2026, 08:11 ET Rocket One Reports Approximately $8.4 Million in Cash and Cash Equivalents and Outlines Strategy Across AI Infrastructure, Spintronic Computing for Space and Defense Markets
infrastructure, and defense technologies.Legacy Biotechnology PortfolioWhile Rocket One has embarked on a new strategic direction, the Company continues to maintain ownership of the biotechnology assets developed under Hoth Therapeutics.This
More news about: Rocket One Inc.
Jun 15, 2026, 08:10 ET Celltaxis Names Co-Founder Eileen Heffernan as CEO to Accelerate Growth and Expand Leadership in Lymphatic Disease Therapeutics
Celltaxis, a clinical-stage biotechnology company dedicated to developing novel therapies for lymphatic diseases, today announced the promotion of Eileen Heffernan to Chief Executive Officer.
More news about: Celltaxis
Jun 15, 2026, 08:00 ET H.I.G. Capital Completes Sale of Celerion, Highlighting a Period of Robust Exit Activity
Advantage.About CelerionCelerion is a clinical research organization that provides comprehensive clinical trial solutions to pharmaceutical and biotechnology clients conducting early clinical research throughout North America, Europe, and Asia. The Company serves its clients through a global network of
More news about: H.I.G. Capital
Jun 15, 2026, 08:00 ET Halia Therapeutics Receives FDA Fast Track Designation for Ofirnoflast (HT-6184) in Lower-Risk Myelodysplastic Syndromes
for lower-risk MDS and other inflammasome-driven diseases.About Halia TherapeuticsHalia Therapeutics is a clinical-stage biotechnology company headquartered in Lehi, Utah, developing first-in-class therapies that target inflammasome-driven disease biology. The company focuses on
More news about: Halia Therapeutics
Jun 15, 2026, 07:00 ET Bambusa Therapeutics Presents Positive Preliminary Multiple Ascending Dose Phase 1 Data for BBT002 at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026
BOSTON, June 15, 2026 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa Therapeutics), a clinical-stage biotechnology company advancing next-generation, long-acting bispecific antibodies for immunology and inflammation, today announced positive preliminary data
More news about: Bambusa Therapeutics, Inc.
Jun 15, 2026, 06:00 ET Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029
than one million patient lives through ten commercialized products across over 100 global markets and is licensed to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen
More news about: Halozyme Therapeutics, Inc.
Jun 14, 2026, 03:15 ET Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jun 13, 2026, 11:50 ET Kos Biotechnology Partners Announces Third Closing of Global Life Sciences Fund at $123 Million
alongside a strategic investment in a San Francisco-based biotechnology company to be announced soon. Multiple additional investments are slated for completion later this year.About Kos Biotechnology PartnersKos Biotechnology Partners is a global life sciences investment firm based
More news about: Kos Biotechnology Partners
Jun 13, 2026, 11:40 ET MGI Tech Showcases Expanding Genomics Ecosystem at ESHG 2026 with New IVD Partnering Program and OEM Collaborations
focus lies in research & development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. We provide real-time, multi-omics, and a full spectrum of digital equipment and systems for precision medicine, agriculture, healthcare, and various
More news about: MGI Tech Co., Ltd.
Jun 13, 2026, 11:15 ET Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Jun 12, 2026, 20:51 ET Angel Yeast Releases 2025 Sustainability Report as Company Marks 40th Anniversary
themes—Stable Development, Strong Momentum, Green Ecosystem, and Warm Care—the report outlines the company's performance in food safety, risk management, biotechnology innovation, environmental stewardship, and employee well-being. A dedicated ESG section covers governance, stakeholder engagement, and materiality
More news about: Angel Yeast
Jun 12, 2026, 17:19 ET The Inner Circle acknowledges, Michael M. Pennock, MD, MBiot, DABR as a Pinnacle Lifetime Member
Bachelor of Science in psychology, with a concentration in neuroscience, from Davidson College in North Carolina. He went on to earn his Master of Biotechnology from Penn State University, and his Doctor of Medicine from Penn State College of Medicine. He completed his residency in radiation oncology, serving
More news about: The Inner Circle
Jun 12, 2026, 10:01 ET In Vitro Toxicology Testing Market worth $20.97 billion by 2031 | MarketsandMarkets™
needs.The pharmaceutical & biotechnology companies segment accounted for the largest share in the in vitro toxicology testing services market in 2025.By end user, the in vitro toxicology testing services market has been segmented into pharmaceutical & biotechnology companies, consumer care
More news about: MarketsandMarkets
Jun 12, 2026, 09:00 ET Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity
TÜBINGEN, Germany, June 12, 2026 /PRNewswire/ -- Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, today announced positive top-line efficacy results from its completed
More news about: Acousia Therapeutics GmbH
Jun 12, 2026, 08:59 ET From Cancer Drugs to Kilowatts: A NASDAQ Company's Bet on the AI Power Crunch
[email protected](604) 265-2873SOURCES:LIXTE Biotechnology Holdings, Inc. — "LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems…" (company press release, June 2026; acquisition, NOMAD platform, permitting advantages,
More news about: USA News Group
Jun 12, 2026, 04:00 ET Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity
TÜBINGEN, Germany, June 12, 2026 /PRNewswire/ -- Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, today announced positive top-line efficacy results from its completed
More news about: Acousia Therapeutics GmbH